| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - We have read with great interest the results of the recently published prospective analysis of the Grupo Espa?ol de Linfomas/Trasplante Autólogo de Médula Ósea (GELTAMO) phase II trial.1 This paper may have an extraordinary impact on decision-making in clinical practice worldwide. Javier Briones and colleagues analyzed treatment efficacy of autologous stem cell transplant (ASCT) after 90Y-ibritumomab tiuxetan plus BEAM conditioning regimen in relapsed or refractory patients with diffuse large B-cell lymphoma (DLBCL). We fully agree with their statement that 90Y-ibritumomab tiuxetan is safe and its application leads to high treatment response rates and promising survival in DLBCL patients with a very poor prognosis. However, we are not sure about the treatment response evaluation and survival analyses. First, this study included 30 evaluable patients who received treatment. Three patients died during or shortly after ASCT and did not undergo the final re-staging procedures three months after ASCT. We understand that treatment response is analyzed on an intention-to-treat basis (i.e. calculated for all 30 patients) but it does not reflect the efficacy of 90Y-ibritumomab tiuxetan plus BEAM conditioning. It is our opinion that a more detailed analysis of only those patients (n=27) who were evaluable for the response should have been made. Second, the sum of all treatment responses is 31 (18 complete, 3 partial and 10 progressions), probably due to the inclusion of one primarily progressive, and thus untreated, case. Furthermore, it is not completely clear whether all patients were evaluated for response using PET-CT. Data are shown for only 21 of them despite the statement that treatment response was to be evaluated using PET-based Cheson criteria.2
- We have read with great interest the results of the recently published prospective analysis of the Grupo Espa?ol de Linfomas/Trasplante Autólogo de Médula Ósea (GELTAMO) phase II trial.1 This paper may have an extraordinary impact on decision-making in clinical practice worldwide. Javier Briones and colleagues analyzed treatment efficacy of autologous stem cell transplant (ASCT) after 90Y-ibritumomab tiuxetan plus BEAM conditioning regimen in relapsed or refractory patients with diffuse large B-cell lymphoma (DLBCL). We fully agree with their statement that 90Y-ibritumomab tiuxetan is safe and its application leads to high treatment response rates and promising survival in DLBCL patients with a very poor prognosis. However, we are not sure about the treatment response evaluation and survival analyses. First, this study included 30 evaluable patients who received treatment. Three patients died during or shortly after ASCT and did not undergo the final re-staging procedures three months after ASCT. We understand that treatment response is analyzed on an intention-to-treat basis (i.e. calculated for all 30 patients) but it does not reflect the efficacy of 90Y-ibritumomab tiuxetan plus BEAM conditioning. It is our opinion that a more detailed analysis of only those patients (n=27) who were evaluable for the response should have been made. Second, the sum of all treatment responses is 31 (18 complete, 3 partial and 10 progressions), probably due to the inclusion of one primarily progressive, and thus untreated, case. Furthermore, it is not completely clear whether all patients were evaluated for response using PET-CT. Data are shown for only 21 of them despite the statement that treatment response was to be evaluated using PET-based Cheson criteria.2 (en)
|
| Title
| - Ibritumomab tiuxetan plus BEAM in refractory Diffuse Large B-cell Lymphoma. Reply to !Ibritumomab tiuxen plus BEAM in refractory Diffuse Large B-cell Lymphoma
- Ibritumomab tiuxetan plus BEAM in refractory Diffuse Large B-cell Lymphoma. Reply to !Ibritumomab tiuxen plus BEAM in refractory Diffuse Large B-cell Lymphoma (en)
|
| skos:prefLabel
| - Ibritumomab tiuxetan plus BEAM in refractory Diffuse Large B-cell Lymphoma. Reply to !Ibritumomab tiuxen plus BEAM in refractory Diffuse Large B-cell Lymphoma
- Ibritumomab tiuxetan plus BEAM in refractory Diffuse Large B-cell Lymphoma. Reply to !Ibritumomab tiuxen plus BEAM in refractory Diffuse Large B-cell Lymphoma (en)
|
| skos:notation
| - RIV/61989592:15110/14:33150763!RIV15-MSM-15110___
|
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| |
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/61989592:15110/14:33150763
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - relapse; autologous transplantation; ibritumomab tiuxetan; diffuse large B-cell lymphoma, ibritumomab tiuxetan, diffuse large B-cell lymphoma (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| |
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| - Haematologica: the hematology journal
|
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Hluší, Antonín
- Procházka, Vít
|
| issn
| |
| number of pages
| |
| http://bibframe.org/vocab/doi
| - 10.3324/haematol.2014.107177
|
| http://localhost/t...ganizacniJednotka
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)